GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » 3-Year Dividend Growth Rate

PMCB (PharmaCyte Biotech) 3-Year Dividend Growth Rate : 0.00% (As of Jan. 2025)


View and export this data going back to 2003. Start your Free Trial

What is PharmaCyte Biotech 3-Year Dividend Growth Rate?

PharmaCyte Biotech's Dividends per Share for the three months ended in Jan. 2025 was $0.00.

The historical rank and industry rank for PharmaCyte Biotech's 3-Year Dividend Growth Rate or its related term are showing as below:

PMCB's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 9.6
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

PharmaCyte Biotech's Dividend Payout Ratio for the three months ended in Jan. 2025 was 0.00. As of today, PharmaCyte Biotech's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of PharmaCyte Biotech's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, PharmaCyte Biotech's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCyte Biotech's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's 3-Year Dividend Growth Rate falls into.


;
;

PharmaCyte Biotech 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

PharmaCyte Biotech  (NAS:PMCB) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

PharmaCyte Biotech's Dividend Payout Ratio for the quarter that ended in Jan. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Jan. 2025 )/ EPS without NRI (Q: Jan. 2025 )
=0/ -0.104
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech 3-Year Dividend Growth Rate Related Terms>

PharmaCyte Biotech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » 3-Year Dividend Growth Rate
Comparable Companies
ERNA ACXP LYRA RLMD OCEA KPRX TSBX CHRO INDP APLM VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
Website
https://pharmacyte.com
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Executives
Wayne Remell Walker director 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Robert Weinstein director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Jack E Stover director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Daniel Stuart Farb director 100 ESSEX RD., CHESTNUT HILL MA 02467
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Daniel Allen director 299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Matthias Loehr director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Yuen Thomas C K director
Carlos Trujillo director, officer: CFO 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Kenneth L. Waggoner director, officer: Chairman, CEO, Pres and GC 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Gerald W Crabtree director, officer: Chief Science Officer 12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904
Thomas Liquard director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653
Raymond Cf Tong director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099
Michael M Abecassis director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099